Dr. Sacco on Upfront Treatments for Head and Neck Cancer

Video

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

Data suggests that higher-dose cisplatin is superior to weekly-dose regarding local regional control. There is a trend to improved disease-free survival and overall survival, however further research is needed.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Related Content
stock.adobe.com

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024
Article
Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

September 2nd 2021
Podcast
Oliver Lantz, MD, PhD, a clinical immunologist and researcher at Institut Curie in Paris, France

Investigational Vaccine TG4050 Shows Early Clinical Benefit in HPV– Head and Neck Cancers

April 9th 2024
Article
Deborah J. Wong, MD, PhD, HS associate clinical professor of medicine at the University of California Los Angeles School of Medicine

Atezolizumab Fails to Improve Survival Outcomes After Definitive Local Therapy in High-Risk HNSCC

April 8th 2024
Article